Vitexin is a sugar-bound plant compound from mung bean seed coats, hawthorn and passionflower, sold as a concentrated extract. In cells and rodents it switches on the body's antioxidant defences, quiets inflammation and slows sugar release from starch. Nothing comparable has been shown in people, and one harm, interference with thyroid hormone production, has better evidence than any benefit. (Full Review)

Protocol

Standardized extract route

300–1,800 mg daily

Hawthorn extract standardized on vitexin, in divided doses

Mung bean seed coat extract route

20–100 mg daily

Combined vitexin and isovitexin; the seed coat supplies over 95% of the plant's vitexin

Best time of day

With the largest carbohydrate-containing meal

Split dosing with meals is the rational default given the short half-life

Time to effect

Post-meal glucose blunting

Immediate

Occurs within the same meal

Anti-inflammatory and antioxidant endpoints

Two to eight weeks

Where they occur at all; rodent studies only

Benefits

Low: Blunting of post-meal glucose rise; activation of endogenous antioxidant defences; protection of blood-vessel lining cells; protection of heart muscle after interrupted blood flow; neuroprotection after interrupted brain blood flow; preservation of memory and learning under chemical blockade; protection of kidney tissue in injury models; protection of liver tissue in injury models; suppression of inflammatory and pain signaling; calming and anti-seizure activity; antidepressant-like activity

Speculative: Chemoprevention and tumor suppression; extension of lifespan through insulin signaling; support of bone density through reduced bone breakdown

Contraindications

Untreated or unstable hypothyroidism, or thyroid-stimulating hormone above the laboratory reference range

Documented iodine deficiency, or urinary iodine below 100 µg/L

Pregnant or breastfeeding women

Warfarin with an unstable international normalized ratio, or a narrow-margin CYP3A substrate such as tacrolimus

Children and adolescents

Child-Pugh Class B or C liver impairment

Key Interactions

Levothyroxine and antithyroid drugs (methimazole, propylthiouracil)

Warfarin and other CYP2C9 substrates (phenytoin, celecoxib, glipizide)

CYP3A substrates (statins, calcium channel blockers, tacrolimus, direct oral anticoagulants)

OATP2B1 and OATP1A2 substrates (fexofenadine, rosuvastatin, atorvastatin)

Over-the-counter agents (ibuprofen, naproxen, omeprazole, cimetidine)

Supplements with additive thyroid effects (soy isoflavones, raw cruciferous concentrates, millet-based powders)

Supplements with additive glucose lowering (berberine, chromium picolinate, bitter melon, fenugreek)

Supplements with additive antiplatelet effects (fish oil, ginkgo, high-dose vitamin E)

Hawthorn preparations for heart failure

Risk & Side Effects

Medium: Suppression of thyroid hormone synthesis

Low: Interference with drug-metabolizing enzymes; interference with drug uptake transporters; additive blood-sugar lowering; digestive intolerance from plant-source extracts

Speculative: Estrogen-pathway modulation; unknown safety in pregnancy and lactation; blunting of exercise-induced adaptation; undefined long-term toxicology

Monitoring

Marker	Target	Why
TSH	0.5–2.0 mIU/L	Earliest signal of the documented thyroid-synthesis interference
Free T4	1.0–1.5 ng/dL	Confirms whether a rising TSH reflects genuine reduced hormone output
Free T3	3.0–4.0 pg/mL	Detects impaired conversion, the step the rat coupling data implicate
TPO antibodies	Negative, below assay cut-off	Identifies autoimmune thyroid disease, the group most exposed to added inhibition
Urinary iodine concentration	100–199 µg/L	Iodine sufficiency is the main factor that blunts C-glycosylflavone goitrogenicity
Fasting glucose	75–90 mg/dL	Tracks the glycemic mechanism and flags additive lowering with medication
HbA1c	4.8–5.4%	Confirms whether post-meal glucose blunting translates into a durable change
ALT and AST	ALT below 25 U/L (men), below 20 U/L (women)	Screens for liver strain from a concentrated botanical extract
Creatinine with eGFR	eGFR above 90 mL/min/1.73m²	Impaired clearance prolongs exposure and widens the interaction window
hs-CRP	Below 1.0 mg/L	The most accessible readout of the anti-inflammatory claim
International normalized ratio (warfarin users)	Stable	CYP2C9 inhibition can raise warfarin levels and bleeding risk

Cadence: Baseline before the first dose; thyroid panel and international normalized ratio at 8 weeks; glucose, glycated hemoglobin and high-sensitivity C-reactive protein at 12 weeks; full set every 6–12 months thereafter for as long as use continues

Qualitative Assessment

Cold intolerance, unexplained fatigue, dry skin or constipation — the earliest subjective signs of falling thyroid output
Post-meal energy stability and reduced afternoon slump, the subjective correlate of blunted glucose excursions
Digestive tolerance: bloating, loose stools or cramping in the first four weeks
Sleep onset latency and morning restedness, relevant if a passionflower-based product is the delivery vehicle
Unusual bruising or prolonged bleeding from minor cuts, the practical signal of additive antiplatelet or anticoagulant effect

Vitexin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment